Novartis AG (NVSEF)
NVSEF Stock Price Chart
Explore Novartis AG interactive price chart. Choose custom timeframes to analyze NVSEF price movements and trends.
NVSEF Company Profile
Discover essential business fundamentals and corporate details for Novartis AG (NVSEF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
26 Apr 2010
Employees
75.88K
Website
https://www.novartis.comCEO
Vasant Narasimhan
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NVSEF Financial Timeline
Browse a chronological timeline of Novartis AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 29 Jan 2026
Upcoming earnings on 28 Oct 2025
Earnings released on 17 Jul 2025
EPS came in at $2.06 falling short of the estimated $2.35 by -12.34%, while revenue for the quarter reached $14.84B , beating expectations by +8.38%.
Earnings released on 29 Apr 2025
EPS came in at $1.85 falling short of the estimated $2.11 by -12.32%, while revenue for the quarter reached $13.62B , missing expectations by -2.01%.
Earnings released on 31 Jan 2025
EPS came in at $1.41 falling short of the estimated $1.80 by -21.67%, while revenue for the quarter reached $13.56B , beating expectations by +5.61%.
Dividend declared on 31 Jan 2025
A dividend of $3.96 per share was announced, adjusted to $3.98. The dividend was paid on 13 Mar 2025.
Earnings released on 29 Oct 2024
EPS came in at $1.57 falling short of the estimated $1.94 by -19.07%, while revenue for the quarter reached $13.17B , beating expectations by +2.97%.
Earnings released on 18 Jul 2024
EPS came in at $1.59 falling short of the estimated $1.85 by -14.05%, while revenue for the quarter reached $12.59B , beating expectations by +1.10%.
Earnings released on 23 Apr 2024
EPS came in at $1.31 falling short of the estimated $1.68 by -22.02%, while revenue for the quarter reached $11.46B , beating expectations by +0.22%.
Earnings released on 5 Mar 2024
EPS came in at $4.11 surpassing the estimated $1.65 by +149.09%, while revenue for the quarter reached $11.78B , missing expectations by -0.91%.
Dividend declared on 31 Jan 2024
A dividend of $3.75 per share was announced, adjusted to $3.74. The dividend was paid on 11 Mar 2024.
Stock split effective on 4 Oct 2023
Shares were split 211 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at $0.85 falling short of the estimated $1.67 by -49.16%, while revenue for the quarter reached $12.09B , missing expectations by -2.61%.
Earnings released on 30 Jun 2023
EPS came in at $1.11 falling short of the estimated $1.64 by -32.32%, while revenue for the quarter reached $13.94B , beating expectations by +3.43%.
Earnings released on 8 Jun 2023
EPS came in at $1.08 falling short of the estimated $1.45 by -25.52%, while revenue for the quarter reached $13.21B , beating expectations by +3.86%.
Earnings released on 1 Feb 2023
EPS came in at $1.52 surpassing the estimated $1.40 by +8.57%, while revenue for the quarter reached $13.09B , missing expectations by -1.00%.
Dividend declared on 1 Feb 2023
A dividend of $3.42 per share was announced, adjusted to $3.22. The dividend was paid on 13 Mar 2023.
Earnings released on 25 Oct 2022
EPS came in at $1.58 surpassing the estimated $1.55 by +1.94%, while revenue for the quarter reached $12.84B , missing expectations by -0.33%.
Earnings released on 19 Jul 2022
EPS came in at $1.56 surpassing the estimated $1.50 by +4.00%, while revenue for the quarter reached $13.09B , beating expectations by +1.59%.
Earnings released on 26 Apr 2022
EPS came in at $1.46 surpassing the estimated $1.44 by +1.39%, while revenue for the quarter reached $12.81B , beating expectations by +1.55%.
Earnings released on 2 Feb 2022
EPS came in at $1.40 falling short of the estimated $1.42 by -1.41%, while revenue for the quarter reached $13.52B , beating expectations by +1.46%.
Dividend declared on 2 Feb 2022
A dividend of $3.34 per share was announced, adjusted to $3.17. The dividend was paid on 10 Mar 2022.
Earnings released on 25 Oct 2021
EPS came in at $1.71 surpassing the estimated $1.65 by +3.64%, while revenue for the quarter reached $13.37B .
Earnings released on 21 Jul 2021
EPS came in at $1.66 surpassing the estimated $1.54 by +7.79%, while revenue for the quarter reached $13.29B .
Earnings released on 27 Apr 2021
EPS came in at $1.52 falling short of the estimated $1.56 by -2.56%, while revenue for the quarter reached $12.69B .
Dividend declared on 3 Feb 2021
A dividend of $3.24 per share was announced, adjusted to $3.09. The dividend was paid on 8 Mar 2021.
Earnings released on 26 Jan 2021
EPS came in at $1.34 falling short of the estimated $1.37 by -2.19%, while revenue for the quarter reached $13.03B .
Earnings released on 27 Oct 2020
EPS came in at $1.52 surpassing the estimated $1.45 by +4.83%, while revenue for the quarter reached $12.54B .
NVSEF Stock Performance
Access detailed NVSEF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.